Cytokinetics to Present at September Investor Conferences
September 05 2017 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that
Robert I. Blum, President and Chief Executive Officer, is scheduled
to present a corporate update at the following investor
conferences:
- Morgan Stanley 15th Annual Global Healthcare
Conference on Monday, September 11, 2017 at 2:15 PM EDT at
the Grand Hyatt in New York
- Rodman & Renshaw 19th Annual Global Investment
Conference on Tuesday, September 12, 2017 at 2:10 PM EDT
at the Lotte New York Palace Hotel in New York
- Cantor Fitzgerald Global Healthcare Conference
on Tuesday, September 26, 2017 at 1:05 PM EDT at the
InterContinental New York Barclay Hotel in New York
Interested parties may access the live webcast
of these presentations by visiting the Investors & Media
section of the Cytokinetics website at www.cytokinetics.com. The
webcast replays of the presentations will be archived on the
Presentations page within the Investors & Media section of
Cytokinetics' website for 90 days following the conclusion of each
event.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics’ lead drug candidate
is tirasemtiv, a fast skeletal muscle troponin activator
(FSTA). Tirasemtiv is the subject of VITALITY-ALS, an
international Phase 3 clinical trial in patients with
ALS. Tirasemtiv has been granted orphan drug designation
and fast track status by the U.S. Food and Drug
Administration (FDA) and orphan medicinal product designation
by the European Medicines Agency for the potential
treatment of ALS. Cytokinetics is preparing for the
potential commercialization of tirasemtiv in North
America and Europe and has granted an option
to Astellas Pharma Inc. (“Astellas”) for development and
commercialization in other countries. Cytokinetics is
collaborating with Astellas to develop CK-2127107, a
next-generation FSTA. CK-2127107 has been granted orphan drug
designation by the FDA for the potential treatment of
SMA. CK-2127107 is the subject of three ongoing Phase 2 clinical
trials enrolling patients with spinal muscular atrophy, chronic
obstructive pulmonary disease and ALS. Astellas is also conducting
a Phase 1b clinical trial of CK-2127107 in elderly adults with
limited mobility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other countries. Astellas holds an
exclusive worldwide license to develop and commercialize
CK-2127107. Licenses held by Amgen and Astellas are
subject to Cytokinetics' specified co-development and
co-commercialization rights. For additional information
about Cytokinetics,
visit http://www.cytokinetics.com/.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the “Act”). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act’s safe harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to planned
presentations, and the properties and potential benefits of
Cytokinetics’ drug candidates and potential drug candidates. Such
statements are based on management’s current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to, potential
difficulties or delays in the development, testing, regulatory
approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and
that Cytokinetics' drug candidates and potential drug
candidates may have unexpected adverse side effects or inadequate
therapeutic efficacy. For further information regarding these and
other risks related to Cytokinetics’ business, investors should
consult Cytokinetics’ filings with the Securities and Exchange
Commission.
Contact:
Cytokinetics
Diane Weiser
Vice President, Corporate Communications, Investor Relations
(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Oct 2023 to Oct 2024